Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine As Conversion Therapy of Locally Advanced Colorectal Cancer

Neoadjuvant chemotherapy has gained acceptance in treating locally advanced breast cancer, esophageal cancer, gastric cancer, and rectal cancer. However, the role of neoadjuvant chemotherapy for locally advanced colon cancer is still in the exploratory stage. The objective of this study is to explore the efficacy and safety of nanoliposomal irinotecan and oxaliplatin combined with capecitabine as a novel conversion therapy for locally advanced colorectal cancer patients.

Trial Details

NCT ID
NCT06405139
Phase
PHASE2
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Nanoliposomal Irinotecan, Oxaliplatin plus Capecitabine
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • With a full understanding of the study, each participant volunteered to participate in this study and signed the informed consent (ICF) with good c…
  • Age ≥18 and ≤70.
  • ECOG physical status score is 0 or 1.
  • Expected survival period ≥ 12 weeks.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →